Dosimetric advantages of proton therapy compared with photon therapy using an adaptive strategy in cervical cancer

J. A. J. van de Schoot, Agustinus; de Boer, Peter; F. Crama, Koen; Visser, Jorrit; J. A. Stalpers, Lukas; R. N. Rasch, Coen; Bel, Arjan

doi:10.6084/m9.figshare.3082186

ionc_a_1139179_sm1897.pdf (5.03 MB)

Dosimetric advantages of proton therapy compared with photon therapy using an adaptive strategy in cervical cancer

journal contribution

posted on 2016-03-03, 10:36 authored by Agustinus J. A. J. van de Schoot, Peter de Boer, Koen F. Crama, Jorrit Visser, Lukas J. A. Stalpers, Coen R. N. Rasch, Arjan Bel

Background Image-guided adaptive proton therapy (IGAPT) can potentially be applied to take into account interfraction motion while limiting organ at risk (OAR) dose in cervical cancer radiation therapy (RT). In this study, the potential dosimetric advantages of IGAPT compared with photon-based image-guided adaptive RT (IGART) were investigated.

Material and methods For 13 cervical cancer patients, full and empty bladder planning computed tomography (CT) images and weekly CTs were acquired. Based on both primary clinical target volumes (pCTVs) [i.e. gross tumor volume (GTV), cervix, corpus-uterus and upper part of the vagina] on planning CTs, the pretreatment observed full range primary internal target volume (pITV) was interpolated to derive pITV subranges. Given corresponding ITVs (i.e. pITVs including lymph nodes), patient-specific photon and proton plan libraries were generated. Using all weekly CTs, IGART and IGAPT treatments were simulated by selecting library plans and recalculating the dose. For each recalculated IGART and IGAPT fraction, CTV (i.e. pCTV including lymph nodes) coverage was assessed and differences in fractionated substitutes of dose-volume histogram (DVH) parameters (V_15Gy, V_30Gy, V_45Gy, D_mean, D_2cc) for bladder, bowel and rectum were tested for significance (Wilcoxon signed-rank test). Also, differences in toxicity-related DVH parameters (rectum V_30Gy, bowel V_45Gy) were approximated based on accumulated dose distributions.

Results In 92% (96%) of all recalculated IGAPT (IGART) fractions adequate CTV coverage (V_95% >98%) was obtained. All dose parameters for bladder, bowel and rectum, except the fractionated substitute for rectum V_45Gy, were improved using IGAPT. Also, IGAPT reduced the mean dose to bowel, bladder and rectum significantly (p < 0.01). In addition, an average decrease of rectum V_30Gy and bowel V_45Gy indicated reductions in toxicity probabilities when using IGAPT.

Conclusion This study demonstrates the feasibility of IGAPT in cervical cancer using a plan-library based plan-of-the-day approach. Compared to photon-based IGART, IGAPT maintains target coverage while significant dose reductions for the bladder, bowel and rectum can be achieved.